Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30095461 | 1.00 | KMT2A (0.54) | KMT2AEPHX2PTPRCMALT1TDP1 | |
| Hydrochloric Acid SCHEMBL455447 | 0.99 | KMT2A (0.53) | KMT2AEPHX2PTPRCMALT1TDP1 | |
| SCHEMBL29616475 | 0.91 | KMT2A (0.54) | KMT2AEPHX2PTPRCCASP3 | |
| SCHEMBL19931854 | 0.91 | KMT2A (0.54) | KMT2AEPHX2PTPRCCASP3 | |
| SCHEMBL13247459 | 0.90 | KMT2A (0.57) | KMT2AEPHX2MALT1CASP3 | |
| SCHEMBL30678165 | 0.90 | KMT2A (0.57) | KMT2AEPHX2MALT1CASP3 | |
| SCHEMBL1007491 | 0.88 | KMT2A (0.58) | KMT2AEPHX2CASP3 | |
| SCHEMBL5557644 | 0.88 | KMT2A (0.60) | KMT2AEPHX2MALT1CASP3 | |
| Hydrochloric Acid SCHEMBL7876414 | 0.87 | KMT2A (0.57) | KMT2AEPHX2CASP3 | |
| SCHEMBL26172640 | 0.87 | KMT2A (0.60) | KMT2AEPHX2MALT1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2017025968-A1 | RADIATION EMITTING PEPTIDE NUCLEIC ACID CONJUGATES AND USES THEREOF FOR DIAGNOSIS, IMAGING, AND TREATMENT OF DISEASES, CONDITIONS AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-02-16 | — | — | WO | disclosed |
| EP-2268607-B9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-05-13 | — | — | EP | disclosed |
| EP-2268607-B1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-02-18 | — | — | EP | disclosed |
| US-8859490-B2 | Peptide nucleic acid monomers and oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-10-14 | — | — | US | disclosed |
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-03-15 | — | — | US | disclosed |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHONOLOGICAL UNIVERSITY (SG) | 2011-10-06 | — | — | US | disclosed |
| EP-2268607-A2 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | Cti Bio (KR) | 2011-01-05 | — | — | EP | disclosed |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7282575-B2 | Functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| US-7282575-B2 | Functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| EP-1381392-A4 | SYNTHETIC CATALYST FOR SELECTIVE CLEAVAGE OF PROTEIN AND METHOD FOR SELECTIVE CLEAVAGE OF PROTEIN USING THE SAME | TS CORP (KR) | 2005-03-23 | — | — | EP | disclosed |
| EP-1381392-A1 | SYNTHETIC CATALYST FOR SELECTIVE CLEAVAGE OF PROTEIN AND METHOD FOR SELECTIVE CLEAVAGE OF PROTEIN USING THE SAME | TS Corporation (KR) | 2004-01-21 | — | — | EP | disclosed |
| US-20020165365-A1 | Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same | ARTZYME BIOTECH CORPORATION (KR) | 2002-11-07 | — | — | US | disclosed |
| WO-2002085413-A1 | SYNTHETIC CATALYST FOR SELECTIVE CLEAVAGE OF PROTEIN AND METHOD FOR SELECTIVE CLEAVAGE OF PROTEIN USING THE SAME | TS CORPORATION (KR) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | KMT2A 3492/4885EPHX2 3651/4885PTPRC 3584/4885 |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KMT2A 2365/4885EPHX2 593/4885PTPRC 2120/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | KMT2A 1219/4885EPHX2 1799/4885PTPRC 1883/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KMT2A 2365/4885EPHX2 593/4885PTPRC 2120/4885 |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | KMT2A 3492/4885EPHX2 3651/4885PTPRC 3584/4885 |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | NSUN3, RNGTT, NSUN2 | KMT2A 2806/4885EPHX2 2034/4885PTPRC 3263/4885 |
| US-20020165365-A1 | Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same | CPN1, RNPEP, ANPEP | KMT2A 3366/4885EPHX2 3746/4885PTPRC 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.